PTGX Q3 2021 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-21.6% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$34M-329.8% margin

Net Income

-$34M-328.6% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+354.1%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$373M

Total Liabilities

$44M

Stockholders' Equity

$330M

Cash & Equivalents

$121M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$13M	-21.6%
Gross Profit	$10M	$13M	-21.6%
Operating Income	-$34M	-$8M	-336.5%
Net Income	-$34M	-$8M	-335.5%

Revenue Segments

License And Service

$8M100%